ANEBULO PHARMACEUTICALS INC's ticker is ANEB and the CUSIP is 034569103. A total of 13 filers reported holding ANEBULO PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $14,649,972 | -4.9% | 5,366,290 | 0.0% | 12.50% | -5.8% |
| Q1 2024 | $15,401,252 | +18.6% | 5,366,290 | 0.0% | 13.27% | +56.9% |
| Q4 2023 | $12,986,422 | -16.1% | 5,366,290 | +5.9% | 8.46% | -23.3% |
| Q3 2023 | $15,477,516 | +30.0% | 5,066,290 | 0.0% | 11.03% | +48.3% |
| Q2 2023 | $11,905,782 | -19.0% | 5,066,290 | 0.0% | 7.44% | -17.6% |
| Q1 2023 | $14,692,241 | +19.7% | 5,066,290 | 0.0% | 9.03% | +36.2% |
| Q4 2022 | $12,279,167 | -13.4% | 5,066,290 | 0.0% | 6.63% | -17.4% |
| Q3 2022 | $14,186,000 | -18.9% | 5,066,290 | +50.7% | 8.02% | -13.5% |
| Q2 2022 | $17,486,000 | -26.6% | 3,362,713 | 0.0% | 9.28% | +7.4% |
| Q1 2022 | $23,808,000 | +15.1% | 3,362,713 | 0.0% | 8.64% | +35.2% |
| Q4 2021 | $20,681,000 | -5.6% | 3,362,713 | +0.6% | 6.40% | -2.0% |
| Q3 2021 | $21,900,000 | -4.0% | 3,343,565 | 0.0% | 6.52% | +6.5% |
| Q2 2021 | $22,803,000 | – | 3,343,565 | – | 6.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| 22NW, LP | 3,362,713 | $17,486,000 | 9.28% |
| LVW Advisors, LLC | 700,000 | $3,640,000 | 0.74% |
| Ikarian Capital, LLC | 181,199 | $942,000 | 0.17% |
| MANGROVE PARTNERS IM, LLC | 399,219 | $2,076,000 | 0.10% |
| BOOTHBAY FUND MANAGEMENT, LLC | 17,333 | $90,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 7,141 | $37,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 20 | $0 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| UBS Group AG | 2,909 | $15,000 | 0.00% |
| BlackRock Inc. | 7,333 | $38,000 | 0.00% |